Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells

Type 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for chemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Cieniewicz, Brandon, Uyeda, Molly Javier, Chen, Ping (Pauline), Sayitoglu, Ece Canan, Liu, Jeffrey Mao-Hwa, Andolfi, Grazia, Greenthal, Katharine, Bertaina, Alice, Gregori, Silvia, Bacchetta, Rosa, Lacayo, Norman James, Cepika, Alma-Martina, Roncarolo, Maria Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485690/
https://www.ncbi.nlm.nih.gov/pubmed/33054128
http://dx.doi.org/10.3324/haematol.2020.263129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485690/
https://www.ncbi.nlm.nih.gov/pubmed/33054128
http://dx.doi.org/10.3324/haematol.2020.263129

Ejemplares similares